Articles related to IMMUNOTHERAPY

Combined omalizumab-OIT therapy demonstrated an impressive 50-percentage-point advantage over placebo in food challenge success rates for children with multiple food allergies.

The discovery of I-NCMs’ ability to simultaneously patrol blood vessels and infiltrate tumor environments opens new possibilities for treating therapy-resistant cancers.

Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.

The study’s findings highlight the complex interplay between CAR T cell therapy and cytokine signaling in AML treatment, suggesting new avenues for improving outcomes in this challenging disease.

Chemotherapy-free regimens for Ph+ ALL have shown complete response rates of 94-100% with minimal toxicity, potentially eliminating the need for stem cell transplant in many patients.

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.